Effects of fasting on warfarin sensitivity index in patients undergoing cardiovascular surgery.


Journal

European journal of clinical pharmacology
ISSN: 1432-1041
Titre abrégé: Eur J Clin Pharmacol
Pays: Germany
ID NLM: 1256165

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 26 06 2018
accepted: 30 10 2018
pubmed: 22 11 2018
medline: 7 9 2019
entrez: 22 11 2018
Statut: ppublish

Résumé

Warfarin shows large inter- and intra-individual variabilities in its pharmacokinetics and pharmacodynamics. Sufficient understanding of factors affecting the response to warfarin is necessary to achieve improved outcomes for warfarin therapy. In this study, we evaluated effects of fasting on the anticoagulant properties of warfarin. We conducted a retrospective observational study involving a total of 58 patients, who received cardiovascular surgeries and subsequent warfarin therapy. The effect of dietary intake on the anticoagulant properties with warfarin was assessed by measurement of the international normalized ratio of prothrombin time (PT-INR): the anticoagulant activities of warfarin were expressed as the warfarin sensitivity index (WSI). Additionally, fluctuations in WSI during the study period were obtained as differences between the maximum and minimum WSI. The maximum PT-INR and WSI values were significantly higher for patients who were fasting for different reasons during the postoperative period than those in the group without reduced dietary intake. The differences between maximum and minimum WSI in the fasting group significantly increased compared with those in the groups with moderate or no reduced dietary intake. Meanwhile, effects of other markers of clinical conditions including the baseline Child-Pugh score and Charlson Comorbidity Index on WSI were not significant. Our results indicate that postoperative fasting was significantly associated with the anticoagulation activity of warfarin. In patients fasting for different reasons during the postoperative period, closer control of PT-INR values and warfarin adjustments may be required to avoid adverse effects such as bleeding in warfarin treatment.

Identifiants

pubmed: 30460405
doi: 10.1007/s00228-018-2592-4
pii: 10.1007/s00228-018-2592-4
doi:

Substances chimiques

Anticoagulants 0
Warfarin 5Q7ZVV76EI

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

561-568

Références

Thromb Haemost. 1999 Mar;81(3):396-9
pubmed: 10102468
Drug Metab Dispos. 2000 Oct;28(10):1202-9
pubmed: 10997941
Clin Pharmacokinet. 2001;40(8):587-603
pubmed: 11523725
Clin Pharmacol Ther. 2003 Sep;74(3):215-21
pubmed: 12966365
JAMA. 2003 Nov 26;290(20):2685-92
pubmed: 14645310
Am J Med. 2004 May 15;116(10):651-6
pubmed: 15121490
J Clin Pharm Ther. 2004 Oct;29(5):485-90
pubmed: 15482394
Ann Pharmacother. 2005 Jun;39(6):1008-12
pubmed: 15855242
Blood. 2005 Oct 1;106(7):2329-33
pubmed: 15947090
Clin Pharmacol Ther. 2006 Apr;79(4):291-302
pubmed: 16580898
Blood. 2007 Mar 15;109(6):2419-23
pubmed: 17110451
Clin Pharmacol Ther. 2007 Apr;81(4):529-38
pubmed: 17301738
J Thromb Haemost. 2008 Jul;6(7):1226-8
pubmed: 18466315
Clin Pharmacol Ther. 2008 Nov;84(5):581-8
pubmed: 18685566
Br J Haematol. 2010 May;149(4):598-605
pubmed: 20151978
Blood Rev. 2012 Jan;26(1):1-14
pubmed: 21914559
Am J Clin Nutr. 1990 May;51(5):846-52
pubmed: 2333843
J Thromb Thrombolysis. 2014 Jul;38(1):105-14
pubmed: 23928870
J Thromb Haemost. 2014;12(3):349-54
pubmed: 24354801
J Health Popul Nutr. 2014 Sep;32(3):400-10
pubmed: 25395903
Biol Pharm Bull. 2014;37(12):1990-3
pubmed: 25451849
Drug Metab Dispos. 2015 Jun;43(6):819-28
pubmed: 25795462
J Pharm Health Care Sci. 2016 Aug 04;2:17
pubmed: 27493787
J Saudi Heart Assoc. 2017 Jan;29(1):1-6
pubmed: 28127212
Clin Pharmacokinet. 2017 Oct;56(10):1231-1244
pubmed: 28229374
Clin Nutr. 2017 Jun;36(3):623-650
pubmed: 28385477
J Clin Pharm Ther. 2017 Oct;42(5):591-597
pubmed: 28503837
Br J Surg. 1973 Aug;60(8):646-9
pubmed: 4541913
J Clin Epidemiol. 1994 Nov;47(11):1245-51
pubmed: 7722560
Lancet. 1993 Nov 20;342(8882):1255-62
pubmed: 7901582
Clin Pharmacokinet. 1996 Jul;31(1):47-64
pubmed: 8827399
Br J Clin Pharmacol. 1998 Jun;45(6):525-38
pubmed: 9663807

Auteurs

Yoshiki Katada (Y)

Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Sakyo-ku, Kyoto, 606-8507, Japan.

Shunsaku Nakagawa (S)

Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Sakyo-ku, Kyoto, 606-8507, Japan.

Akiko Nishimura (A)

Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Sakyo-ku, Kyoto, 606-8507, Japan.

Yu-Ki Sato (YK)

Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Sakyo-ku, Kyoto, 606-8507, Japan.

Hiromi Taue (H)

Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Sakyo-ku, Kyoto, 606-8507, Japan.

Katsuyuki Matsumura (K)

Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Sakyo-ku, Kyoto, 606-8507, Japan.

Kazuhiro Yamazaki (K)

Department of Cardiovascular Surgery, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto, 606-8507, Japan.

Kenji Minakata (K)

Department of Cardiovascular Surgery, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto, 606-8507, Japan.

Ikuko Yano (I)

Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Sakyo-ku, Kyoto, 606-8507, Japan.
Department of Pharmacy, Kobe University Hospital, Chuo-ku, Kobe, 650-0017, Japan.

Tomohiro Omura (T)

Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Sakyo-ku, Kyoto, 606-8507, Japan.

Satoshi Imai (S)

Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Sakyo-ku, Kyoto, 606-8507, Japan.

Atsushi Yonezawa (A)

Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Sakyo-ku, Kyoto, 606-8507, Japan.

Yuki Sato (Y)

Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Sakyo-ku, Kyoto, 606-8507, Japan.

Takayuki Nakagawa (T)

Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Sakyo-ku, Kyoto, 606-8507, Japan.

Kenji Minatoya (K)

Department of Cardiovascular Surgery, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto, 606-8507, Japan.

Kazuo Matsubara (K)

Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Sakyo-ku, Kyoto, 606-8507, Japan. kmatsuba@kuhp.kyoto-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH